The Cooper Companies (COO)
(Delayed Data from NSDQ)
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 6:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 6:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD
by Zacks Equity Research
Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.
A Dive into The Cooper Companies (COO) International Revenue Trends and Forecasts
by Zacks Equity Research
Examine the evolution of The Cooper Companies' (COO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
3 Top Performing Stocks to Buy After Earnings
by Shaun Pruitt
Able to exceed top and bottom line expectations on Wednesday, here are three intriguing companies to invest in as their stocks continue to outperform the broader market.
COO Stock Gains on Q3 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
Cooper Companies' solid segmental results led to an encouraging fiscal third-quarter performance, driving up share prices in after-hours trading.
Compared to Estimates, The Cooper Companies (COO) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Cooper Companies (COO) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 5.49% and 0.57%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
PDCO Stock Falls on Q1 Earnings & Sales Miss, Gross Margin Up Y/Y
by Zacks Equity Research
Patterson Companies' first-quarter fiscal 2025 results reflect the negative impact of a cyberattack on its vendor, Change Healthcare.
Will The Cooper Companies (COO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
The Cooper Companies (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Unveiling The Cooper Companies (COO) Q3 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for The Cooper Companies (COO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2024.
Zacks.com featured highlights ServiceNow, Boston Scientific and Cooper
by Zacks Equity Research
ServiceNow, Boston Scientific and Cooper have been highlighted in this Screen of The Week article.
3 Profitable S&P 500 Stocks With Room to Run: NOW, BSX, COO
by Tirthankar Chakraborty
ServiceNow (NOW), Boston Scientific (BSX) and The Cooper Companies (COO) have been selected as the top picks with a high net income ratio.
Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 6.98% and 1.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 220.79% and 487.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 32% and 4.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CooperCompanies (COO) Acquires obp Surgical to Boost Portfolio
by Zacks Equity Research
CooperSurgical, a unit of CooperCompanies (COO), acquires obp Surgical for $100 million, adding innovative single-use surgical retractors and suction devices to its portfolio.
Labcorp (LH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 4.23% and 0.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Cooper Companies (COO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for The Cooper Companies (COO) give insight into how the company performed in the quarter ended April 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Cooper Companies (COO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 2.41% and 0.56%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cooper Companies (COO) in Q2 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.